Ki-CONNECT Now
Access
EN
Our vision
Facilities
Our team
What we do
Get in touch
Ki-CONNECT Now
Access
EN
Ki-CONNECT Now
Apr. 24, 2025
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarcinoma with an IDH1 Mutation (S095031-210)
Ki-CONNECT Now一覧へ
